Supernus to Participate in Two Upcoming Investor Conferences Read more about Supernus to Participate in Two Upcoming Investor Conferences
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference Read more about Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results Read more about Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression Read more about Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results Read more about Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease Read more about Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women Read more about Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference Read more about Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference Read more about Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
Supernus Announces Third Quarter 2024 Financial Results Read more about Supernus Announces Third Quarter 2024 Financial Results